Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Giugliano, Robert P., Pedersen, Terje R., Park, Jeong-Gun, De Ferrari, Gaetano M., Gaciong, Zbigniew A., Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose ORCID: 0000-0002-8844-0718, Schiele, Francois, Mach, Francois, Ott, Brian R., Kanevsky, Estelle, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M., Keech, Anthony C., Sever, Peter S. and Sabatine, Marc S. (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 390 (10106). S. 1962 - 1972. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

Sabatine, Marc S., Leiter, Lawrence A., Wiviott, Stephen D., Giugliano, Robert P., Deedwania, Prakash, De Ferrari, Gaetano M., Murphy, Sabina A., Kuder, Julia F., Gouni-Berthold, Ioanna, Lewis, Basil S., Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C., Sever, Peter S. and Pedersen, Terje R. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol., 5 (12). S. 941 - 951. NEW YORK: ELSEVIER SCIENCE INC. ISSN 2213-8587

This list was generated on Fri Mar 24 04:10:29 2023 CET.